Microcap Ledger

Tickers · $CYPH

Cypherpunk Technologies Inc. $CYPH

By Microcap Ledger desk · CIK 0001509745

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Pharmaceutical Preparations
Headquarters
Cambridge, MA
Fiscal year end
December 31
Shares outstanding
107,764,382 [10-Q 2026-08-12]
as of 2026-08-10

Sources: [10-K 2026-03-16]

What the company doesAI summary of filing

Cypherpunk Technologies Inc. operates two primary business segments. First, it is a privacy technology company implementing a digital asset treasury strategy focused on acquiring and holding Zcash (ZEC), a privacy-focused cryptocurrency, with the stated objective of accumulating at least 5% of circulating ZEC supply over time. Second, through its subsidiary Leap Therapeutics, the company develops biomarker-targeted antibody therapies for cancer treatment, with its lead program sirexatamab (DKN-01) currently in clinical development for colorectal cancer and a preclinical program FL-501 targeting GDF-15 for cachexia-related indications. The company is clinical-stage with respect to its drug development operations and pre-revenue as to commercial sales, having raised $58.88 million in October 2025 to fund its digital asset strategy and ongoing operations. [10-K 2026-03-16]

Segments: Zcash (ZEC) digital asset treasury, Sirexatamab (DKN-01) - colorectal cancer, FL-501 - cachexia and related indications, Privacy technology and ecosystem development

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026—−$37.78M −$6.12M$7.62M[10-Q 2026-08-12]
FY ended Dec 2025—$5.00M −$43.90M$14.04M[DEF 14A 2026-04-29]
FY ended Dec 2024—−$68.00M −$60.30M$47.25M[DEF 14A 2026-04-29]
Quarterly cash burn
−$3.06M
Cash runway Estimate
~7.5 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-0838,317,897[10-Q 2024-11-13]
2025-03-2041,257,602[10-K 2025-03-26]
2025-05-0941,439,529[10-Q 2025-05-13]
2025-08-1141,439,529[10-Q 2025-08-14]
2025-11-1056,651,840[10-Q 2025-11-12]
2026-03-1189,979,619[10-K 2026-03-16]
2026-05-12106,464,482[10-Q 2026-05-14]
2026-08-10107,764,382[10-Q 2026-08-12]
Shelf registration
S-3 filed 2024-05-10; declared effective 2024-05-23 [S-3 2024-05-10]

Listing status

Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2026-07-218-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-07-21]
2026-03-098-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-03-09]
2025-09-118-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-09-11]
2025-03-178-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-03-17]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-09-25Oei Khing Djiensell168,750$3.92[4 2026-09-25]
2026-09-23Martin Patricia A.sell50,000$3.86[4 2026-09-25]
2026-08-26Dietz Thomas Johnsell20,000$1.72[4 2026-08-27]
2026-08-17Mcevoy William Patrick Iiiother16,570,852$0.00[4 2026-08-19]
2026-08-17Winklevoss Capital Fund, Llcother16,570,852$0.00[4 2026-08-19]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.